SCHEMBL10133033

SCHEMBL10133033

CN1CCN(CCOc2ccc(-c3ccc(CCNC(=O)c4ccccc4)nc3)cc2)CC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TUBB4A P04350 5/20 0.53
TUBB P07437 5/20 0.53
TUBA3C P0DPH7 5/20 0.53
TUBA1B P68363 5/20 0.53
TUBA4A P68366 5/20 0.53
TUBB4B P68371 5/20 0.53
TUBB3 Q13509 5/20 0.53
TUBB2A Q13885 5/20 0.53
TUBB8 Q3ZCM7 5/20 0.53
TUBA3E Q6PEY2 5/20 0.53
TUBA1A Q71U36 5/20 0.53
TUBA1C Q9BQE3 5/20 0.53
TUBB6 Q9BUF5 5/20 0.53
TUBB2B Q9BVA1 5/20 0.53
TUBB1 Q9H4B7 5/20 0.53
SRC P12931 2/20 0.53
ABL1 P00519 1/20 0.53
LYN P07948 1/20 0.53
BCR P11274 1/20 0.53
NPC1 O15118 4/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10132965 0.87 MEN1 (0.58) NPC1RAB9AKCNA5DRD3LTA4H
SCHEMBL10133018 0.82 TUBB4A (0.55) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL11917546 0.79 TUBB4A (0.81) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL10133034 0.79 TUBB4A (0.70) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL10133072 0.79 HIF1A (0.59) NPC1RAB9AMEN1KMT2AMAPT
SCHEMBL10133014 0.78 TUBB4A (0.58) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL10132780 0.77 HPGD (0.62) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL11754722 0.76 HDAC2 (0.59) NPC1RAB9ADRD3MAPTSMN1; SMN2
SCHEMBL10133016 0.76 TUBB4A (0.57) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL10133028 0.75 TUBB4A (0.57) TUBB4ATUBBTUBA3CTUBA1BTUBA4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8124605-B2 Compositions and methods for modulating a kinase cascade KINEX PHARMACEUTICALS, LLC (US) 2012-02-28 US disclosed
US-8124605-B2 Compositions and methods for modulating a kinase cascade KINEX PHARMACEUTICALS, LLC (US) 2012-02-28 US disclosed
US-20090149510-A1 Compositions and methods for modulating a kinase cascade OAKTREE FUND ADMINISTRATION, LLC 2009-06-11 US disclosed
US-20090149510-A1 Compositions and methods for modulating a kinase cascade OAKTREE FUND ADMINISTRATION, LLC 2009-06-11 US disclosed
WO-2009009041-A2 COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE KINEX PHARMACEUTICALS, LLC (US) 2009-01-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090149510-A1 Compositions and methods for modulating a kinase cascade MAP3K6, MAP3K4, MAP3K3 TUBB4A 3036/4885TUBB 2736/4885TUBA3C 3585/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.